Abstract
Purpose :
Neovascular glaucoma stage III (NVG III) represents the advanced stage of neovascular glaucoma, distinguished by secondary angle closure and poor visual prognosis. This study aims to delineate the demographic characteristics, etiology, treatments, and outcomes of NVG III within a tertiary care ophthalmic center in Mexico.
Methods :
This retrospective observational clinical study focused on patients diagnosed with Neovascular Glaucoma (NVG) stage III between January 2020 and December 2022.
Patients were stratified based on best-corrected visual acuity (BCVA): Group 1 included patients with BCVA ≥ light perception (LP) and color discrimination (CD), while Group 2 comprised patients with BCVA LP and no CD or blindness. For patients in Group 1 with a follow-up period of less than one month and Group 2, demographic information, BCVA, and etiology were systematically collected. In cases of groups with a follow-up exceeding one month, demographic information, medical history, BCVA, etiology, clinical characteristics, treatment modalities, and visual outcomes for both eyes were documented.
Results :
A total of 385 patients, with a mean of 58.84 ± 10.81 years, participated in the study. In the BCVA ≥ LP and CD group (n=59) with a follow-up >1 month, the mean follow-up duration was 57.57 ± 43.90 weeks. Patients waited an average of 128.76 ± 256.35 days before seeking consultation for symptom progression. Diabetes was present in 95% of patients, with 8.93% receiving no treatment, and 39% had hypertension. The comparison of initial BCVA LogMar 1.97 ± 0.72 to final 1.83 ± 0.97 revealed no statistically significant difference (p > 0.05). Legal blindness was observed in 27.27% at the end of the follow-up period.
Conclusions :
This study sheds light on the comprehensive systemic and clinical features of NVG III, providing valuable insights into its management and outcomes in the Mexican population.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.